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ABSTRACT 
The purpose of this investigation was undertaken to design a simple, rapid, cost effective and highly efficient process to fabricate intensely bitter taste of 
Amlodipine Besylate by complexing drug with Aminoalkyl methacrylate copolymer (Eudragit EPO) in different ratios by Hot-Melt Extrusion method. Taste 
masked complex were analyzed with FTIR, DSC and XRD. DCP were tested for Hardness, Thickness, Weight Variation, Drug Content, Water absorption and 
In  vitro  Dispersion  Test  in  Simulated  Salivary  Fluid  pH  6.8.  Taste  masked  granules  were  directly  compressed  into  tablets  using  Kollodion  CL  and 
Croscarmellose  Sodium  (Ac-Di-Sol)  as  superdisintegrants.  Tablets  of  batch  F6  containing  mannitol  and  6%  wt/wt  of  Kollodion  CL  showed  faster 
disintegration with in 24 sec and drug release (t90, 180sec) at Phosphate Buffer pH 6.8. The observed polymer interaction and reduced crystallinity may be 
reason for increased dissolution rate. Thus results conclusively demonstrate successful  masking of taste, disintegration and dissolution of the formulated 
tablets. 
Keywords: Drug Polymer Complex, Hot Extrusion Method, Amlodipine Besylate, Kollodion CL, Croscarmellose Sodium, Oro Dispersible Tablets. 
 
INTRODUCTION 
Recent  advances  in  novel  drug-delivery  system  aims  to 
enhance  the  safety  and  efficacy  of  the  drug  molecule  by 
formulating  a  dosage  form  being  convenient  for  the 
administration.  Difficulty  in  swallowing  (i.e.  dysphagia)  is 
experienced  by  patients  such  as  paediatrics,  geriatric, 
bedridden, disabled, mentally ill, including motion sickness 
and  sudden  episodes  of  allergic  attacks,  hence  resulting  in 
higher incidence of noncompliance and ineffective therapy
1. 
In order to solve this problem and improve patient acceptance 
and compliance, the development of solid dosage forms that 
disintegrate  rapidly  or  dissolve  even  when  taken  orally 
without  water  is  being  undertaken.  oral  route  of  drug 
administration have wide acceptance, up to 50-60% of solid 
dosage forms are popular because of natural, uncomplicated, 
convenient,  ease  of  administration,  accurate  dosage,  self-
medication,  pain  avoidance  and  most  importantly  patient 
compliance.  The  most  popular  solid  dosage  forms  being 
tablets and capsules, one important drawback of these dosage 
forms for patient is the difficulty to swallow. Swallowing of 
solid  dosage  forms  like  tablets  and  capsules  and  improper 
dosing  of  suspension  and  emulsion  may  produce  difficulty 
for  young  children  because  of  incomplete  development  of 
muscular and nervous system and elderly patients suffering 
from  dysphasia,  Parkinson's  disorder  and  tremor.  Other 
groups that may experience problems using conventional oral 
dosage  forms include the  mentally ill, the developmentally 
disabled  patients,  patients  who  are  uncooperative,  or  on 
reduced liquid intake plans  or nauseated, patients having  a 
persistent cough or a gag-reflex and travellers who may not 
have access to water
2. Oral fast-disintegrating dosage forms 
(tablet or a capsule) are a relatively novel dosage technology 
that  involves  the  rapid  disintegration  or  dissolution  of  the 
dosage  form  into  a  solution  or  suspension  in  the  mouth 
without  the  need  for  water
3-5.  The  dosage  form  begins  to 
disintegrate  immediately  after  coming  into  contact  with 
saliva,  with  complete  disintegration  normally  occurring 
within 30-50 s after administration
6. The solution containing 
the active ingredients is swallowed and the active ingredients 
are then absorbed through the gastrointestinal epithelium to 
reach the target and produce the desired effect. Tablet is the 
most widely used dosage form because of its convenience in 
terms  of  self-administration,  compactness  and  ease  in 
manufacturing
7. Orally disintegrating tablets are also called 
as Orodispersible tablets, quick-disintegrating tablets, mouth-
dissolving tablets, fast-disintegrating tablets, fast dissolving 
tablets,  rapid-dissolving  tablets,  porous  tablets  and  rapid 
melts.  However,  of  all  the  above  terms,  the  United  States 
Pharmacopoeia  (USP)  approved  these  dosage  forms  as 
Orodispersible  tablets  (ODTs).  Recently,  the  European 
Pharmacopoeia has used the term Orodispersible tablets for 
tablets that disperse readily and within 3 min in the mouth 
before  swallowing.  The  United  States  Food  and  Drug 
Administration  define  ODT  as  “a  solid  dosage  form 
containing  medicinal  substance  or  active  ingredient  which 
disintegrates rapidly usually within a matter of seconds when 
placed upon the tongue.” The disintegration time for ODTs 
generally  ranges  from  several  seconds  to  about  a  minute
8. 
Other advantages  of ODTs that have been investigated are 
their potential to increase the bioavailability of poorly water 
soluble drug through enhancing the dissolution profile of the 
drug
9.  Moreover,  pharmaceutical  companies  also  have 
commercial reasons for formulating ODTs. As a drug reaches 
the end of its patent, the development and formulation of the 
drug into new dosage forms allow pharmaceutical companies 
to  extend  the  patent  life  and  “market  exclusivity”
10.  The 
ODTs  could  be  prepared  using  various  techniques  such  as 
tablet  moulding,  spray  drying,  sublimation,  lyophilization, 
solid dispersion, or addition of disintegrants
11-15.  The  basic 
approach  to  the  development  of  ODTs  is  the  use  of 
superdisintegrants  such  as  Croscarmellose  sodium  and 
sodium  starch  glycolate.  Another  approach  used  in 
developing  ODTs  is  maximizing  the  pore  structure  of  the 
tablet matrix. Freeze drying and vacuum drying techniques 
have been tried by researchers to maximize the pore structure 
of  the  tablet  matrix
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cumbersome  and  yields  a  fragile  and  hygroscopic  product. 
Vacuum drying  along with the sublimation of  volatilizable 
ingredient  has  been  employed  to  increase  tablet  porosity. 
While  in  designing  dispersible  tablets,  it  is  possible  to 
achieve effective taste masking as well as a pleasant feel in 
the  mouth.  The  main  criterion  for  ODTs  is  the  ability  to 
disintegrate or dissolve rapidly in saliva of the oral cavity in 
15 to 60 s and have a pleasant mouth feel. To improve the 
quality of life and treatment compliance, great efforts have 
been  made  to  develop  fast-disintegrating  tablets  (FDTs)  in 
the  oral  cavity,  using  jelly,  water-absorbing  and  swelling-
gelated  materials  or water-soluble  polymers
19.  However, of 
all  the  above  terms,  United  States  pharmacopoeia  (USP) 
approved these dosage forms as ODTs. Recently, European 
Pharmacopoeia  has  used  the  term  Orodispersible  tablet  for 
tablets  that  disperses  readily  and  within  3  min  in  mouth 
before  swallowing.  United  States  Food  and  Drug 
Administration (FDA) defined ODT as "A solid dosage form 
containing  medicinal  substance  or  active  ingredient  which 
disintegrates rapidly usually within a matter of seconds when 
placed upon the tongue." The disintegration time for ODTs 
generally ranges from several seconds to about a minute
20. 
 
MATERIALS 
Amlodipine Besylate was chosen as an active ingredient and 
it  was  gift  sample  from  Dr.  Reddy’s  Laboratories, 
Hyderabad, Andhra Pradesh, India. Eudragit EPO, Mannitol, 
Kollidon  CL,  Croscarmellose  Sodium,  Aspartame  and 
Magnesium stearate were purchased from colorcon, Mumbai, 
India. All other reagents were of analytical grade. 
 
METHOD 
Preparation of Drug - Polymer Complex 
The drug polymer complex (DPC) was prepared by Hot- melt 
Extrusion using different ratio of Amlodipine Besylate  and 
Eudragit EPO (1:1 and 1:2). Initially, Amlodipine Besylate is 
passed through #60 sieves. Later Eudragit EPO is melted at a 
temperature  of  100 
0C.  After  the  complete  melting  of 
polymer  the  drug  is  incorporated  slowly  with  continuous 
stirring.  Then  after  uniform  mixing  the  mixture  is  cooled, 
finely  grounded and passed through #30 sieve  followed by 
passing through # 60 sieves.  
 
Formulation of Oral Dispersible Tablets 
Oral dispersible tablets were prepared by Direct Compression 
Method.  Initially,  Amlodipine  Besylate  and  Drug  Polymer 
complex  is  weighed  individually  for  each  formulation. 
Kollidon CL, Cross carmellose sodium, Mannitol, Aspartame 
is passed through sieve No. 60 and individually weighed for 
each formulation (Table 1). These are mixed with DPC on 
polyethylene  paper.  Similarly,  Aerosil  and  Magnesium 
sterate  are  individually  passed  through  sieve  No.  60  and 
individual quantities are weighed and mixed thoroughly with 
the  above  mixture  and  finely  mixed  for  10  Minutes.  The 
mixed  blend  was  punched  into  individual  biconvex  tablets 
weighing 100 mg on a multi punch tablet machine using 6 
mm punch for compression. 20 tablets were punched of each 
formulation.  Similarly,  blank  tablets  without  containing 
Eudragit EPO are weighed and punched as per formulation 
FB6 and SB6. 
 
 
 
 
 
Evaluation 
Characterization of drug-polymer complex 
Fourier Transform Infrared (FTIR) Spectroscopy 
FTIR spectra were obtained on Shimadzu FTIR Model 8400-
S spectrometer. The Spectra was recorded as a dispersion of 
the sample in Potassium Bromide in IR disk (2 mg sample in 
200 mg KBr) with the scanning range of 400 to 4000 cm
-1 
and the resolution was 1 cm 
-1. 
 
X-Ray Diffraction (XRD) Studies 
X-ray  Diffraction  analysis  was  carried  out  to  evaluate  the 
degree of crystallinity. The pure Amlodipine Besylate, pure 
Eudragit  EPO,  and  drug  polymer  complex  (1:1)  were 
subjected  to  powder  XRD  (P.W.  1729,  X-Ray  Generator, 
Philips,  Netherland)  at  2Ө  angles  between  20  and  38
0  in 
increments of 0.40
21. 
 
Drug Content 
DPC  equivalent  to  10  mg  of  drug  was  stirred  by  using 
magnetic stirrer with 100 ml of Methanol for 60 minutes, till 
the entire drug leached out from complex, than the solution 
was filter through whatman filter paper. Further solution was 
diluted with methanol and the drug content was determined 
spectrophotometrically at 239 nm
21. 
 
Characeterization of Powder Blend 
Angle of Repose  
Angle of repose was determined using funnel method. The 
blend  was  poured  through  a  funnel  that  can  be  raised 
vertically  until  a  maximum  cone  height  (h)  was  obtained. 
Radius of the heap (r) was measured and angle of repose (θ) 
was calculated using the following formula
22-24,  
tanθ= h/r 
 
Bulk Density 
Apparent bulk density (ρb) was determined by pouring the 
blend into a graduated cylinder. The bulk volume (Vb) and 
weight of the powder (M) was determined. The bulk density 
(ρb) was calculated using following formula,  
ρb = Vb/M 
 
Tapped Density 
The  measuring cylinder containing a known  mass of blend 
(M) was tapped for a fixed time (100 tapings). The minimum 
volume (Vt) occupied in the cylinder and weight of the blend 
was measured. The tapped density (ρt) was calculated using 
following formula,  
ρt= Vt/M 
 
Compressibility Index 
The simplest method of measurement of free flow of powder 
is  compressibility,  an  indication  of  the  ease  with  which 
material  can  be  induced  to  flow  and  is  given  by 
compressibility index (I) which is calculated as follows, 
I= {(ρt – ρb)/ρt}*100 
The value below 15% indicates a powder which usually gives rise to 
excellent flow characteristics, whereas above 25% indicate poor flow ability. 
 
Hausner’s Ratio (H) 
This  is  an  indirect  index  of  ease  of  powder  flow.  It  is 
calculated by the following formula,  
Η= ρt/ρb 
Lower Hausner’s ratio (<1.25) indicates better flow properties than higher 
ones (>1.25). 
 
 
 B. Sree Giri Prasad et al. Int. Res. J. Pharm. 2013, 4 (7) 
Page 125 
Post Compression Evaluation  
Uniformity of Weight  
The test was carried out according to the US pharmacopoeia. 
20  tablets,  of  each  formulation  were  individually  weighed 
and the mean  of tablet weights was calculated. Results are 
presented as mean value
25-28. 
 
Hardness 
The fracture strength, which is defined as the force required 
breaking a tablet by radial compression was measured with a 
tablet hardness tester
25-28 (Monsanto hardness tester). 
 
Friability 
The friability of sample of six tablets ware measured using a 
Roche  Friabilator (Electrolab EF-2, USP). Six pre-weighed 
tablets were rotated at 25 rpm for 4 minutes. The tablets were 
then reweighed after removal of fine’s using 60 mesh screens 
and the percentage of weight loss was calculated
25-28. 
 
% Friability = (Loss in weight / Initial weight) × 100 
 
Wetting Time 
The wetting time of the tablets has been measured using a 
simple  procedure.  Five  circular  tissue  papers  of  10  cm 
diameter are placed in a petridish with a 10 cm diameter. Ten 
millimetres of water- containing Eosin, a water-soluble dye, 
is  added  to  petridish.  A  tablet  is  carefully  placed  on  the 
surface  of the tissue paper. The time required for water to 
reach upper surface of the tablet is noted as a wetting time
25-
28. 
 
(%) Water Absorption Ratio 
A piece of tissue paper folded twice was placed in a small 
petridish  (Internal  Diameter  =  6.5  cm)  containing  6  ml  of 
water. A tablet was placed on the paper and the time required 
for  complete  wetting  was  then  measured.  The  water 
absorption  ratio  (R)  was  determined  using  the  following 
equation.
25-28 
 
R = 100 (Wa -Wb) / Wb 
Where, Wb is the weight of the tablet before water absorption and Wa is the 
weight of the tablet after water absorption. 
 
 
Figure 1 
 
Content Uniformity   
For the content uniformity test, ten tablets were weighed and 
pulverized to a fine powder, a quantity of powder equivalent 
to 10 mg of Amlodipine Besylate was extracted in 10 ml of 
methanol and liquid was filtered (0.22 μm membrane filter 
disc  (Millipore  Corporation).  The  drug  content  was 
determined by  measuring the absorbance at 239 nm (using 
UV  Spectrophotometer,  Shimadzu  1800)  after  appropriate 
dilution  with  methanol.  The  drug  content  was  determined 
using  standard  calibration  curve.  The  mean  percent  drug 
content  was  calculated  as  an  average  of  three 
determinations
25-28. 
 
Taste Evaluation 
The  objective  of  this  study  is  to  conduct  and  evaluate  the 
Palatability of different formulations of Amlodipine Besylate 
oral disintegrating tablets. Amlodipine Besylate ODT was a 
new development; reference product is not available for ODT 
in  market  for  this  product  for  comparison  of  the  taste 
evaluation.  Total  16  formulations  were  selected  for  taste 
evaluation study, 14 test formulations (Table 1), one positive 
control  (Placebo  for  Amlodipine  Besylate)  and  one  is 
negative control (Placebo for Taste enhancers like aspartame 
and peppermint flavour). All formulations (formulation code) 
were  randomized.  Each  randomization  order  was  assigned 
with sequence code. For this study were selected 6 healthy 
human volunteers 3 male and 3 Female of age around 21-22 
years and were assigned volunteer code. All the 6 volunteers 
were  evaluated  all  eight  formulations  as  per  the 
randomization  order.  Each  of  the  formulations  were 
transferred  to  HDPE  bottles  and  labelled  only  with 
formulation  code.  Palatability  evaluation  feedback  format 
prepared and submitted to each individual volunteer and were 
provided with instructions before starting study. One tablet of 
each formulation was given to volunteer for palatability study 
evaluation. The time interval between evaluations of each test 
formulation  in  the  same  volunteer  was  30  min,  at  after 
evaluated  each  formulation,  one  half  of  a  bread  slice  was 
given to each volunteer followed by half glass of water and 
cocoa  powder  for  neutralizing  the  taste  buds.  After 
completion of the study, data was compiled and evaluated the 
formulations and allotted the rank for all formulation, based 
on the average value of the each formulation
29. 
 
In vitro dispersion time (with simulated salivary fluid) 
This test is performed to ensure disintegration of tablets in 
the salivary fluid, In vitro dispersion time was measured by 
dropping a tablet in a Petri dish containing 6ml of simulated 
salivary fluid of pH 6.8.
25-28  
 
In vitro Drug Release Study 
In-vitro dissolution studies of the fast disintegrating tablets of 
Amlodipine Besylate formulation were performed according 
to  USP  XXIII  Type-II  dissolution  apparatus  (Electrolab, 
model TDT-06N) employing a paddle stirrer at 50 rpm using 
900  ml  of  pH  6.8  phosphate  buffer  at  37  ±  0.5°C  as 
dissolution  medium.  One  tablet  was  used  in  each  test. 
Aliquots of the dissolution medium (10 ml) were withdrawn 
at  specific  time  intervals  and  replaced  immediately  with 
equal volume of fresh medium. The samples were analyzed 
for  drug  content  by  measuring  the  absorbance  at  239  nm. 
Drug  concentration  was  calculated  from  the  standard 
calibration curve and expressed as cumulative percent drug 
dissolved
25-28. 
 
Statistical Analysis 
The results were analyzed by two tailed Student’s t-test using 
the  Graph  Pad  Instat  Software  (GPIS;  Version:  1.13)
30.
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Table 1: Formulation of Amlodipine Besylate Orodispersible Tablets 
 
Ingredients  F1  F2  F3  F4  F5  F6  FB6  S1  S2  S3  S4  S5  S6  SB6 
Amlodipine Besylate  10  10  10  10  10  10  10  10  10  10  10  10  10  10 
Eudragit EPO  10  10  10  10  10  10  -  10  10  10  10  10  10  - 
Kollidone CL  1  2  3  4  5  6  6  -  -  -  -  -  -  - 
Croscarmellose sodium  -  -  -  -  -  -  -  1  2  3  4  5  6  6 
Mannitol  77.8  76.8  75.8  74.8  73.8  72.8  71.8  77.8  76.8  75.8  74.8  73.8  72.8  83.8 
Aspartame  -  -  -  -  -  -  4  -  -  -  -  -  -  4 
Mg. Sterate  0.6  0.6  0.6  0.6  0.6  0.6  0.6  0.6  0.6  0.6  0.6  0.6  0.6  0.6 
Aerosil  0.6  0.6  0.6  0.6  0.6  0.6  0.6  0.6  0.6  0.6  0.6  0.6  0.6  0.6 
Total Weight  100  100  100  100  100  100  100  100  100  100  100  100  100  100 
*Each value represents mean ± S.D (n=3). 
 
Table 2: Characterisation of Powder Blend 
 
Formulation  Angle of repose  Bulk Density  Tapped Density  Percent compressibility Index  Hausner’s Ratio 
F1  23.29 ± 0.01  0.51 ± 0.01  0.676 ± 0.01  23.71 ± 0.01  1.31 ± 0.01 
F2  22.47 ± 0.02  0.45 ± 0.01  0.526 ± 0.01  14.41 ± 0.01  1.16 ± 0.01 
F3  20.18 ± 0.01  0.45 ± 0.03  0.543 ± 0.04  15.6 ± 0.02  1.18 ± 0.01 
F4  21.8 ± 0.03  0.49 ± 0.01  0.555 ± 0.01  11.76 ± 0.02  1.13 ± 0.02 
F5  23.89 ± 0.01  0.43 ± 0.02  0.515 ± 0.03  16.38 ± 0.01  1.19 ± 0.01 
F6  23.8 ± 0.02  0.41 ± 0.01  0.495 ± 0.01  15.83 ± 0.01  1.18 ± 0.02 
S1  23.12 ± 0.02  0.43 ± 0.01  0.515 ± 0.02  14.91 ± 0.02  1.17 ± 0.01 
S2  23.19 ± 0.02  0.46 ± 0.01  0.549 ± 0.01  15.74 ± 0.01  1.18 ± 0.02 
S3  22.86 ± 0.03  0.43 ± 0.01  0.51 ± 0.01  14.03 ± 0.01  1.16 ± 0.01 
S4  23.61 ± 0.01  0.44 ± 0.01  0.537 ± 0.03  16.96 ± 0.01  1.2 ± 0.01 
S5  24.21 ± 0.02  0.42 ± 0.01  0.532 ± 0.01  19.66 ± 0.01  1.24 ± 0.01 
S6  24.16 ± 0.03  0.42 ± 0.01  0.49 ± 0.01  14.29 ± 0.01  1.16 ± 0.01 
*Each value represents mean ± S.D (n=3). 
 
Table 3: Post Compression Parameters 
 
Formulation  Hardness 
Kg/cm
2 
Thickness 
mm 
Friability 
% 
Avg. Weight 
(mg) 
Content 
uniformity (%) 
Wetting time 
(sec) 
In vitro Dispersion 
time (sec) 
Water Absorption 
Ratio (%) 
F1  3.25 ± 0.01  3.1 ± 0.01  0.64 ± 0.01  100.12 ± 0.03  98.19 ± 0.01  147 ± 0.02  167 ± 0.01  41.6 ± 0.01 
F2  3.26 ± 0.01  3.0 ± 0.01  0.69 ± 0.01  99.32 ± 0.02  97.23 ± 0.01  113 ± 0.01  90 ± 0.02  53.8 ± 0.02 
F3  3.24 ± 0.02  2.9 ± 0.02  0.79 ± 0.01  99.57 ± 0.01  97.76 ± 0.01  91 ± 0.01  79 ± 0.01  74.6 ± 0.01 
F4  3.11 ± 0.02  3.0 ± 0.01  0.94 ± 0.01  98.97 ± 0.01  97.89 ± 0.04  76 ± 0.01  51 ± 0.01  74.3 ± 0.01 
F5  3.06 ± 0.01  2.7 ± 0.02  0.89 ± 0.02  98.68 ± 0.03  97.26 ± 0.03  59 ± 0.02  32 ± 0.02  79.8 ± 0.04 
F6  2.97 ± 0.01  2.8 ± 0.01  0.97 ± 0.03  97.93 ± 0.01  97.48 ± 0.02  45 ± 0.01  24 ± 0.01  80.9 ± 0.01 
FB6  3.02 ± 0.03  3.0 ± 0.01  0.84 ± 0.02  98.62 ± 0.02  99.18 ± 0.02  48 ± 0.02  26 ± 0.03  79.6 ± 0.03 
S1  3.12 ± 0.02  3.2 ± 0.01  0.91 ± 0.02  97.21 ± 0.01  97.42 ± 0.01  148 ± 0.01  185 ± 0.01  39.6 ± 0.02 
S2  3.08 ± 0.01  3.1 ± 0.01  0.89 ± 0.01  98.65 ± 0.01  98.09 ± 0.01  104 ± 0.01  98 ± 0.04  47.2 ± 0.01 
S3  3.02 ± 0.01  2.8 ± 0.02  0.99 ± 0.01  96.32 ± 0.01  97.86 ± 0.01  95 ± 0.01  80 ± 0.01  56.3 ± 0.01 
S4  3.16 ± 0.02  2.9 ± 0.01  0.85 ± 0.01  98.59 ± 0.01  98.01 ± 0.01  82 ± 0.03  67 ± 0.03  69.4 ± 0.02 
S5  3.13 ± 0.01  3.2 ± 0.01  0.74 ± 0.01  98.76 ± 0.01  97.61 ± 0.01  73 ± 0.01  49 ± 0.02  76.3 ± 0.01 
S6  3.07 ± 0.01  3.1 ± 0.01  0.67 ± 0.01  98.94 ± 0.01  98.02 ± 0.01  51 ± 0.01  36 ± 0.01  78.5 ± 0.01 
SB6  3.11 ± 0.01  3.3 ± 0.01  0.73 ± 0.01  98.75 ± 0.01  98.89 ± 0.01  53 ± 0.02  39 ± 0.01  77.4 ± 0.02 
*Each value represents mean ± S.D (n=3). 
 
Table 4: Evaluation of Taste Masking Effect of Orodispersible Formulations 
 
Formulation Code  Average points by Volunteer  Acceptability  Rank 
Negative control  99  Very Good  1 
S6  90  Very good  2 
F6  86  Very good  3 
F5  84  Good  4 
S4  83  Good  5 
SB6  54  acceptable  6 
Positive control  19  worst  7 
 
 
 
After 5 Sec 
 
 
 
After 25 Sec 
 
 
 
After 45 Sec 
Figures 2: Wetting Time of Formulation F6 
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After 6 Sec 
 
 
 
After 10 Sec 
 
 
 
After 24 Sec 
 
Figure 3: In-vitro Dispersion Time 
 
 
 
 
 
 
Figure 4: In-vitro Dissolution Studies of Formulations 
 
 
 
 
 
 
 
Figure 5: FTIR Spectroscopy of Pure Amlodipine Besylate Drug, F6 , S6 Tablet Formulations 
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Pure Drug 
 
 
 
Eudragit EPO 
 
 
 
Eudragit EPO and D P C 
 
Figure 6: X-Ray Diffraction Studies 
 
 
 
Figure 7: Taste Masking Effect of Orodispersible Formulations 
 
RESULTS 
Pre compressional Parameters 
Table  2  shows  the  pre-compressional  parameters  of  power 
blend. There was change in angle of repose from F1 to F6 and 
from S1 – S6. Angle of repose increased from 23.29 to 23.89 
and  23.12  to  24.2  respectively.  Bulk  Density  and  Tapped 
Density of  all formulations  are shown in the  Table 2.  The 
results indicated that both densities range from 0.41 to 0515 
gm/c.c and 0.49 to 0.676 gm/c.c. % Compressibility ranges 
from 11.76 to 23.71 and 14.03 to 19.66% in Kolloidan CL 
and  Croscarmellose  formulation  respectively.  All  the 
formulations showed good and Fair flow properties. 
 
Post Compressional Parameters 
Hardness: Table 3 shows hardness of all tablet formulations. 
The results indicated that no such appreciable changes were 
observed with respect to hardness in all formulations form F1 
to F6 and from S1 – S6. 
 
% Friability: Table 3 shows the friability values of all tablet 
formulations.  The  results  indicated  that  the  %  friability  of 
formulation was between 0.64% and 0.97%. The low values 
of  friability  indicate  that  tablets  were  mechanically  hard 
enough. 
 
Thickness:  Table  3  shows  the  thickness  of  all  tablet 
formulations. The results indicated that the thickness of all 
formulations was between 3.45 to 3.95 mm. 
 
Weight Variation Test: Table 3 shows the average weight of 
all  table  formulations.  The  results  indicated  that  average B. Sree Giri Prasad et al. Int. Res. J. Pharm. 2013, 4 (X) 
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weight  of  all  tablets  formulations  was  between  96.32  to 
100.12 mg. 
 
%  Water  Absorption  Ratio:    Table  3  shows  %  water 
absorption  ratio  of  all  tablet  formulation.  The  results 
indicated  that  formulation  containing  1%  Kollidon  CL 
showed  least  water  absorption.  This  may  be  due  to  less 
swelling property. % water absorption ratio increases from F1 
to F6 and from S1 to S6 as the concentration of kollidon CL 
and croscarmellose increases in tablet formulations. 
 
Wetting  Time:  Table  3  show  wetting  studies.  The  results 
revealed that wetting studies of formulations F2 to F6 were 
significantly lower (p<0.05) than F1 (Figure 4a, 4b and 4c). 
Similarly  wetting  time  of  formulation  S2  to  S6  were 
significantly  lower  (p<0.05)  than  S1  (Figure  2).  It  may  be 
because capillary action was higher in all formulations F1 to 
F6 and from S1 to S6 which absorbs water in higher amounts 
as  concentrations  Kollodion  CL  and  Croscarmellose 
increases. 
 
Drug Content  of Tablets: Drug Content of tablets ranged 
between 97.23 to 99.18%. Results are shown in Table 3. 
 
In-vitro Dispersion Time: The in-vitro dispersion times of 
formulations were in the range of 185-23 sec. Here we could 
clearly observe the effect of the concentration of the Kollidon 
CL  and  Croscarmellose  Sodium  concentration,  as  the 
concentration  increased  the  dispersion  time  decreased.  The 
concentration  above  3%  showed  very  good  results  in 
Kollidon  CL  formulation  and  above  4%  concentration  in 
Croscarmellose sodium. And the formulations F4-F6 and S5-
S6 showed promising results for the ODT and at the same 
time the dispersion time  of  formulations is not effected by 
polymer  complexation  when  compared  with  SB6  and  FB6 
(Figure 3). 
 
In-vitro Release Studies: All the formulations were studied 
for  In-vitro  release  studies.  During  this  study  all  the 
formulations  showed  slight  change  in  the  dissolution  rate 
initially. All the formulations could release 85% of the drug 
with  in  the  12  Minutes.  When  the  formulations  of  F1-F5 
when compared with FB6 the rate dissolution is not affected, 
F6  could  release  90%  of  drug  within  3  minutes  and  FB6 
showed  90%  of  drug  release  in  10  minutes  (approx). 
Similarly, when S6 and SB6 are compared S6 showed 90% 
of drug release in 8 minutes (approx) and SB6 showed 90% 
of drug release in 13 minutes (approx) (Figure 4). 
 
FTIR  Studies  Data:  The  spectrum  of  pure  Amlodipine 
Besylate and formulation F6, S6 are shown in (Figure 5). The 
FTIR spectrum of drug and polymer showed no significant 
shift  or  reduction  in  intensity  of  peaks  of  Amlodipine 
Besylate. 
 
X - Ray Diffraction 
The  x-ray  Diffractogram  of  pure  Amlodipine  Besylate, 
Eudragit  EPO  and  drug  polymer  complex  are  shown  in 
(Figure  6).  The  x  ray  diffraction  confirms  its  crystalline 
nature as evidenced from number of sharp and intense peaks. 
The  diffractogram  of  polymer  (Eudragit  EPO)  showed 
diffused  peak,  indicating  the  amorphous  nature  while  the 
diffraction  pattern  of  drug  polymer  complex  represents 
complete  disappearance  of  crystalline  peaks  of  drug 
especially those situated between 20
o and 600
o. These finding 
suggest the formation of new solid phase with a lower degree 
of crystallinity due to complexation. 
 
Human  Taste  Panel:  The  taste  evaluation  of  Amlodipine 
Besylate was performed by volunteers in the age group of 18 
to 22 yrs. The protocol was explained and written consent as 
obtained  from  volunteers.  The  formulations  of  Amlodipine 
Besylate  were  held  in  the  mouth  for  5  seconds  by  each 
volunteer. Bitterness levels were recorded instantly and then 
after  30  to  150  sec.  The  bitterness  level  was  recorded  as 
positive against Negative controls (Figure 7). 
 
DISCUSSION  
The  demand  for  Oro  dispersible  tablets  has  enormously 
increased  during  the  last  decade,  particularly  for  geriatrics 
and  paediatrics  patients  who  have  difficulty  in  swallowing 
conventional tablets and capsules. Oral administration of the 
drugs is difficult in patients having concomitant vomiting or 
diarrhoea. Oro dispersible dosage forms are advantageous for 
such  patients.  Oro  dispersible  dosage  forms  are  meant  to 
dispersible immediately upon contact with the saliva leading 
to faster release of the drugs in the oral cavity. In the present 
work, mouth dissolving tablets of taste masked Amlodipine 
Besylate were prepared by direct compression. All the tablet 
formulations compressed individually using biconcave 6mm 
punches  in  Rimek  mini  press  1,  a  10  station  rotary 
compression machine. Tablets were evaluated for changes in 
parameters  by  changing  the  concentration  of 
superdisintegrants from 1 to 6% and Eudragit EPO used as 
taste masking agent. Precompressional parameters, angle of 
repose,  %  compressibility  and  Hausner’s  ratio  studies 
indicated that most of the formulations showed fair and good 
flow  properties.  Postcompressional  parameters,  hardness, 
friability,  In-vitro  Dispersion  time,  Wetting  time,  drug 
content  and  dissolution  studies  were  studied.  All  the 
formulations  showed  no  appreciable  change  in  hardness, 
while friability of tablets ranged between 0.64% and 0.91%. 
Drug Content of tablets ranged between 97.23 to 99.57%. In-
vitro dispersion time, formulations containing >5% Kollidon 
CL  and  5%  of  Croscarmellose  Sodium  were  found  to  be 
promising.  The  In-vitro  dispersion  time  of  Amlodipine 
Besylate tablets prepared by Kollidon CL was found to be in 
the range of 167-24 Seconds and for those of Croscarmellose 
Sodium  was  found  to  be  in  the  range  of  185-39  Seconds. 
Wetting  time  of  promising  formulations  was  found  to  be 
within 1 minute, which facilitates their faster dispersion in 
the  mouth.  Amongst  the  two  super  disintegrants  used, 
namely,  Kollidon  CL  and  Croscarmellose  Sodium,  the 
Kollidon CL (6%) superdisintegrant was found to be good. 
The  1:1  ratio  of  Eudragit  EPO  to  drug  was  promising  in 
masking  the  bitter  taste  of  Drug.  The  In-vitro  Dissolution 
studies  states  that  formulations  containing  Eudragit  EPO 
polymer didn’t affected on rate of dissolution when compared 
with blank formulations. All the formulations showed 85 % 
of drug release in < 12 minutes. FTIR-spectroscopic studies 
indicated  that  there  are  no  drug–excipient  interactions. 
Similarly X-ray Diffraction studies suggested the formation 
of new solid phase with a lower degree of crystallinity due to 
complexation. From the results of present study indicates the 
complexation of Amlodipine Besylate and Eudragit EPO can 
not only mask its bitter taste significantly but also improve B. Sree Giri Prasad et al. Int. Res. J. Pharm. 2013, 4 (X) 
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the  dissolution  profile.  By  employing  direct  compression 
method, Orodispersible tablets of 100 mg weight with a taste 
acceptable to patients and sufficient structural integrity could 
be prepared. From all the superdisintegrants studied, tablets 
containing 6% Kollidon CL gave the highest improvement in 
disintegration  and  dissolution  profile  of  Amlodipine 
Besylate. 
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